C. Coulet, E. Rouleau, S. M. Caputo, M. Thomassen, and R. Brandao, Acquisition of data (provided animals, acquired and managed patients, provided facilities

O. Sininilkova, S. Demontety, A. Petitalot, A. Ehlen, A. Carrera et al., Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases

R. Wooster, G. Bignell, J. Lancaster, S. Swift, S. Seal et al., Identification of the breast cancer susceptibility gene BRCA2, Nature, vol.378, pp.789-92, 1995.

K. Gudmundsdottir and A. Ashworth, The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability, Oncogene, vol.25, pp.5864-74, 2006.

R. B. Jensen, A. Carreira, and S. C. Kowalczykowski, Purified human BRCA2 stimulates RAD51-mediated recombination, Nature, vol.467, pp.678-83, 2010.

R. Prakash, Y. Zhang, W. Feng, and M. Jasin, Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins, Cold Spring Harb Perspect Biol, vol.7, 2015.

K. Schlacher, H. Wu, and M. Jasin, A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2, Cancer Cell, vol.22, pp.106-122, 2012.

A. ;. Venkitaraman and Y. Miki, Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage, Cancer Sci, vol.343, pp.866-71, 2004.

L. Castéra, S. Krieger, A. Rousselin, A. Legros, J. J. Baumann et al., Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes, Eur J Hum Genet, vol.22, pp.1305-1318, 2014.

T. Walsh and M. C. King, Ten genes for inherited breast cancer, Cancer Cell, vol.11, pp.103-108, 2007.

N. Mavaddat, S. Peock, D. Frost, S. Ellis, R. Platte et al., Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE, J Natl Cancer Inst, vol.105, pp.812-834, 2013.

L. Guidugli, A. Carreira, S. M. Caputo, A. Ehlen, A. Galli et al., Vreeswijk MP; ENIGMA consortium. Functional assays for analysis of variants of uncertain significance in BRCA2, Hum Mutat, vol.35, pp.151-64, 2014.

K. B. Kuchenbaecker, J. L. Hopper, D. R. Barnes, K. A. Phillips, T. M. Mooij et al., Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers, JAMA, vol.317, pp.2402-2418, 2017.

H. Yang, P. D. Jeffrey, J. Miller, E. Kinnucan, Y. Sun et al., BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure, Science, vol.297, pp.1837-1885, 2002.

A. Carreira and S. C. Kowalczykowski, BRCA2: shining light on the regulation of DNA-binding selectivity by RAD51, Cell Cycle, vol.8, pp.3445-3492, 2009.

A. Carreira, J. Hilario, I. Amitani, R. J. Baskin, M. K. Shivji et al., The BRC repeats of BRCA2 modulate the DNA-binding selectivity of RAD51, Cell, vol.136, pp.1032-1075, 2009.

L. Pellegrini, D. S. Yu, T. Lo, S. Anand, M. Lee et al., Insights into DNA recombination from the structure of a RAD51-BRCA2 complex, Nature, vol.420, pp.287-93, 2002.

C. Von-nicolai, Å. Ehlén, C. Martin, X. Zhang, and A. Carreira, A second DNA binding site in human BRCA2 promotes homologous recombination, Nat Commun, vol.7, 2016.

J. Milner, B. Ponder, L. Hughes-davies, M. Seltmann, and T. Kouzarides, Transcriptional activation functions in BRCA2, Nature, vol.386, pp.772-73, 1997.

G. H. May, F. Harris, D. Gillespie, and D. M. Black, The BRCA2 transactivation domain does not interact with JNK, Genes Chromosomes Cancer, vol.25, pp.407-416, 1999.

J. Milner, F. Fuks, L. Hughes-davies, and T. Kouzarides, The BRCA2 activation domain associates with and is phosphorylated by a cellular protein kinase, Oncogene, vol.19, pp.4441-4486, 2000.

H. R. Lin, N. S. Ting, J. Qin, and W. H. Lee, M phase-specific phosphorylation of BRCA2 by Polo-like kinase 1 correlates with the dissociation of the BRCA2-P/CAF complex, J Biol Chem, vol.278, pp.35979-87, 2003.

L. Hughes-davies, D. Huntsman, M. Ruas, F. Fuks, J. Bye et al., EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer, Cell, vol.115, pp.930-939, 2003.

O. Preobrazhenska, M. Yakymovych, T. Kanamoto, I. Yakymovych, R. Stoika et al., BRCA2 and Smad3 synergize in regulation of gene transcription, Oncogene, vol.21, pp.5660-64, 2002.

B. Xia, Q. Sheng, K. Nakanishi, A. Ohashi, J. Wu et al., Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell, vol.22, pp.719-748, 2006.

F. Zhang, Q. Fan, K. Ren, and P. R. Andreassen, PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2, Mol Cancer Res, vol.7, pp.1110-1128, 2009.

D. Muller, E. Rouleau, I. Schultz, S. Caputo, C. Lefol et al., An entire exon 3 germ-line rearrangement in the BRCA2 gene: pathogenic relevance of exon 3 deletion in breast cancer predisposition, BMC Med Genet, vol.12, p.121, 2011.

A. Peixoto, C. Santos, M. Pinheiro, P. Pinto, M. J. Soares et al., International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation, Breast Cancer Res Treat, vol.127, pp.671-79, 2011.

A. Peixoto, C. Santos, P. Rocha, P. Pinto, S. Bizarro et al., Molecular diagnosis of the Portuguese founder mutation BRCA2 c.156_157insAlu. Breast Cancer www

R. Treat, , vol.117, pp.215-232, 2009.

A. Peixoto, C. Santos, P. Rocha, M. Pinheiro, S. Príncipe et al., The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal, Breast Cancer Res Treat, vol.114, pp.31-39, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00486599

S. Caputo, L. Benboudjema, O. Sinilnikova, E. Rouleau, C. Béroud et al., Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases, Nucleic Acids Res, vol.40, pp.992-1002, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01681814

A. B. Spurdle, S. Healey, A. Devereau, F. B. Hogervorst, A. N. Monteiro et al., ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes, Hum Mutat, vol.33, pp.2-7, 2012.

J. S. Martinez, C. Von-nicolai, T. Kim, Å. Ehlén, A. V. Mazin et al., BRCA2 regulates DMC1-mediated recombination through the BRC repeats, Proc Natl Acad Sci USA, vol.113, pp.3515-3535, 2016.

S. E. Plon, D. M. Eccles, D. Easton, W. D. Foulkes, M. Genuardi et al., Unclassified Genetic Variants Working Group. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results, Hum Mutat, vol.29, pp.1282-91, 2008.

C. Bonnet, S. Krieger, M. Vezain, A. Rousselin, I. Tournier et al., Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene, J Med Genet, vol.45, pp.438-484, 2008.

O. Díez, S. Gutiérrez-enríquez, T. Ramón-y-cajal, C. Alonso, J. Balmaña et al., Caution should be used when interpreting alterations affecting the exon 3 of the BRCA2 gene in breast/ovarian cancer families, J Clin Oncol, vol.25, pp.5035-5041, 2007.

M. Nordling, P. Karlsson, J. Wahlström, Y. Engwall, A. Wallgren et al., A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family, Cancer Res, vol.58, pp.1372-75, 1998.

M. Santarosa, A. Viel, and M. Boiocchi, Splice variant lacking the transactivation domain of the BRCA2 gene and mutations in the splice acceptor site of intron 2, Genes Chromosomes Cancer, vol.26, pp.381-82, 1999.

M. Thomassen, A. Blanco, M. Montagna, T. V. Hansen, I. S. Pedersen et al., Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members, Breast Cancer Res Treat, vol.132, pp.1009-1032, 2012.

N. Mavaddat, D. Barrowdale, I. L. Andrulis, S. M. Domchek, D. Eccles et al., Consortium of Investigators of Modifiers of BRCA1/2. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), Cancer Epidemiol Biomarkers Prev, vol.21, pp.134-181, 2012.

A. W. Oliver, S. Swift, C. J. Lord, A. Ashworth, and L. H. Pearl, Structural basis for recruitment of BRCA2 by PALB2, EMBO Rep, vol.10, pp.990-96, 2009.

J. Y. Park, F. Zhang, and P. R. Andreassen, PALB2: the hub of a network of tumor suppressors involved in DNA damage responses, Biochim Biophys Acta, vol.1846, pp.263-75, 2014.

J. Y. Park, T. R. Singh, N. Nassar, F. Zhang, M. Freund et al., Breast cancerassociated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair, Oncogene, vol.33, pp.4803-4815, 2014.

B. Xia, J. C. Dorsman, N. Ameziane, Y. De-vries, M. A. Rooimans et al., Fanconi anemia is associated with a defect in the BRCA2 partner PALB2, Nat Genet, vol.39, pp.159-61, 2007.

A. C. Antoniou, S. Casadei, T. Heikkinen, D. Barrowdale, K. Pylkäs et al., Breast-cancer risk in families with mutations in PALB2, N Engl J Med, vol.371, pp.497-506, 2014.

S. A. Hartford, R. Chittela, X. Ding, A. Vyas, B. Martin et al., Plasticity of BRCA2 function in homologous recombination: genetic interactions of the PALB2 and DNA binding domains, PLoS Genet, vol.12, p.1006236, 2011.

T. Menzel, V. Nähse-kumpf, A. N. Kousholt, D. K. Klein, C. Lundandersen et al., A genetic screen identifies BRCA2 and PALB2 as key regulators of G2 checkpoint maintenance, EMBO Rep, vol.12, pp.705-717, 2011.

R. Buisson, A. M. Dion-côté, Y. Coulombe, H. Launay, H. Cai et al., Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination, Nat Struct Mol Biol, vol.17, pp.1247-54, 2010.

S. M. Sy, M. S. Huen, and J. Chen, PALB2 is an integral component of the BRCA complex required for homologous recombination repair, Proc Natl Acad Sci USA, vol.106, pp.7155-60, 2009.

T. K. Foo, M. Tischkowitz, S. Simhadri, T. Boshari, N. Zayed et al., Compromised BRCA1-PALB2 interaction is associated with breast cancer risk, Oncogene, vol.36, pp.4161-70, 2017.

G. Rigakos and E. Razis, BRCAness: finding the Achilles heel in ovarian cancer, Oncologist, vol.17, pp.956-62, 2012.

W. A. Van-hattem, R. Carvalho, A. Li, G. J. Offerhaus, and M. Goggins, Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas, Int J Clin Exp Pathol, vol.1, pp.343-51, 2008.

I. Cousineau and A. Belmaaza, EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases, Mol Genet Genomics, vol.285, pp.325-365, 2011.

L. C. Walker, Z. S. Fredericksen, X. Wang, R. Tarrell, V. S. Pankratz et al., Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers, Breast Cancer Res, vol.12, p.102, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00622882

J. M. Wong, D. Ionescu, and C. J. Ingles, Interaction between BRCA2 and replication protein A is compromised by a cancer-predisposing mutation in BRCA2, Oncogene, vol.22, pp.28-33, 2003.

I. Bièche and R. Lidereau, Increased level of exon 12 alternatively spliced BRCA2 transcripts in tumor breast tissue compared with normal tissue, Cancer Res, vol.59, pp.2546-50, 1999.

F. Eisinger, B. Bressac, D. Castaigne, P. H. Cottu, J. Lansac et al., Identification and management of hereditary predisposition to cancer of the breast and the ovary (update, Bull Cancer, vol.91, pp.219-256, 2004.

P. Gaildrat, A. Killian, A. Martins, I. Tournier, T. Frébourg et al., Use of splicing reporter minigene assay to evaluate the effect on splicing of unclassified genetic variants, Methods Mol Biol, vol.653, pp.249-57, 2010.

O. Soukarieh, P. Gaildrat, M. Hamieh, A. Drouet, S. Baertdesurmont et al., Exonic splicing mutations are more prevalent than currently estimated and can be predicted by using in silico tools, PLoS Genet, vol.12, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02160189

G. Yeo and C. B. Burge, Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals, J Comput Biol, vol.11, pp.377-94, 2004.

F. O. Desmet, D. Hamroun, M. Lalande, G. Collod-béroud, M. Claustres et al., Human Splicing Finder: an online bioinformatics tool to predict splicing signals, Nucleic Acids Res, vol.37, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00396239

D. Thompson, D. F. Easton, and D. E. Goldgar, A full-likelihood method for the evaluation of causality of sequence variants from family data, Am J Hum Genet, vol.73, pp.652-55, 2003.

D. E. Goldgar, D. F. Easton, G. B. Byrnes, A. B. Spurdle, E. S. Iversen et al., Unclassified Genetic Variants Working Group. Genetic evidence and integration of various data sources for classifying uncertain variants into a single model, Hum Mutat, vol.29, pp.1265-72, 2008.

L. C. Walker, P. J. Whiley, F. J. Couch, D. J. Farrugia, S. Healey et al., Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity, and kConFab Investigators, vol.31, pp.1484-505, 2010.

A. B. Spurdle, F. J. Couch, M. T. Parsons, L. Mcguffog, D. Barrowdale et al., Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia, Breast Cancer Res, vol.16, p.3419, 2014.

S. V. Tavtigian, A. M. Deffenbaugh, L. Yin, T. Judkins, T. Scholl et al., Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent www.oncotarget.com substitutions as neutral, J Med Genet, vol.43, pp.295-305, 2006.

M. P. Vallée, D. Sera, T. L. Nix, D. A. Paquette, A. M. Parsons et al., Adding in silico assessment of potential splice aberration to the integrated evaluation of BRCA gene unclassified variants, Hum Mutat, vol.37, pp.627-666, 2016.